TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: breathing sounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Gingival Crevicular Fluid Bactericidal Permeability Increasing Protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: safety of NVC-422
Endpoint domain: Adverse events/effects
Primary endpoint: antimicrobial effect of NVC-422
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: duration of antimicrobial effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants Adherent to Original Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Receiving Less Than or Equal to (≤) 1 Dose of Study Drug Who Discontinued Treatment for Any Reason
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Withdrawing From the Study Prematurely for Any Reason
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Acceptance and use of technology survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hepatic fat accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Central Macular Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Proportion of patients discontinuing immunosuppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Team Attendance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Team Engagement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Level of Committee Activity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in team-selected health/safety/well-being issue
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Post-intervention change in KOOS pain subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Laboratory investigations (ASOt, ESR, CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of PF-04603629 in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacodynamic responses of glucose, insulin, C-peptide and glucagon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and tolerability of PF-04603629
Endpoint domain: Adverse events/effects
Primary endpoint: Steady-state visual evoked potentials (SSVEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Patients Who Came Off Study for Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Drug levels of Azithromycin, Ivermectin, Diethylcarbamazine, Albendazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gestational age at diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in Duration of Cortical Silent Period (CSP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With a Clinical Response at Week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants in Clinical Remission at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: the moment of knee extension in the gait cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Implant dislocation rate
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of transplant related adverse outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of the intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Complete Small Bowel Transit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in Diabetic Retinopathy Disease Severity Scale (DRSS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Number of Participants With New Vertebral Fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Gastrointestinal Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sustained headache relief for 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Grade III/IV GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Chronic Extensive GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Modified Rankin Scale at Six Months postoperative
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes from Baseline in Modified Rankin Scale at one year postoperative
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Severe Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any Low or High Hematology Laboratory Parameter Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Any Low or High Biochemistry Laboratory Parameter Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S. aureus colonization rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: number of patients who have dose limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Resistivity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From Vessel Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change From Baseline in Glycosylated Hemoglobin (HbA1c) (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Laboratory tests results
Endpoint domain: Adverse events/effects
Primary endpoint: ECG results
Endpoint domain: Adverse events/effects
Primary endpoint: Spirometry monitoring results
Endpoint domain: Adverse events/effects
Primary endpoint: Measurement of plasma cytokines
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Management of obesity, metabolic syndrome and diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rotation of insulin injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Neonatal Composite Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MODS2 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose Area Under the Curve (AUC): Values < 70 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose Area Under the Curve (AUC): Values < 54 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ratio of Self-Reported Hypoglycemic Episodes to Total Hypoglycemic Episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity and specificity of OCTA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to Understand Speech in Noise Background
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of chronic diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Apparent systemic clearance (CL/F) of GSK2800528
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent systemic clearance (CL/F) of adalimumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse event (AE) and Serious Adverse event (SAE) reporting
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of Bemcentinib (BGB324)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Notable Trends in Physical Examination, Vital Signs, Clinical Laboratory Test and Electrocardiogram (ECG) Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SCORAD index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Negative symptom change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient Empowerment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Early onset sepsis infections
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Electrical signal quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in score of Care Service Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time required for staff to respond to events
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: clinical and endoscopic steroid-free remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Event leading to discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Mean Root Coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade of endoscopic recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Post vaccine antibody level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Procedure-related Serious Adverse Events (SAEs) and/or Serious Adverse Device Effects (SADE)
Endpoint domain: Adverse events/effects
Primary endpoint: Post-treatment disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Patch Test Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profile including maximum tolerated dose
Endpoint domain: Adverse events/effects
Primary endpoint: PSP rating scale (PSP-RS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive testing
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Static Balance- area of sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Aberrant Child Checklist subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in total AF burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Goal Setting
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Mental performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in DAS28 (Disease Activity Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stone fragmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Visual Analog Scale pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 75 Foot Laps Completed in 2 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: After-Exercise Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-term change in global brain score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Long-term change in global brain score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Free fatty acid reflux rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Bowel Movements (Stool Frequency)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Visceral Adipose Tissue (VAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Injury surveillance
Endpoint domain: Adverse events/effects
Primary endpoint: Change in serum protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Cosmetic results - BCCT
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in Cosmetic results - Self Evaluation using YBT
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline for Columbia Suicide Severity Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in forearm blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in % Blood Pressure Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Patient Global Impression of Severity (PGI-S) Score in Cohort A at Peak Level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Patient Global Impression of Severity (PGI-S) Score in Cohort A at Trough Level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Patient Global Impression of Severity (PGI-S) Score in Cohort B at Period 1
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Patient Global Impression of Severity (PGI-S) Score in Cohort B at Period 2
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PK parameters (AUC, Cmax, Tmax, t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early Response Assessment by 18F-FDG PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early Response Assessment by 18F-FLT PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival Outcomes According to PET/CT Response
Endpoint domain: Mortality/survival
Primary endpoint: Area Under the Concentration Versus Time Curve From Zero to Tlast (AUC[0-tlast])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pregnancy outcome data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Dosimetric comparison of doses in target volumes and organs at risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean Pain Diary Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Drinking Days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Drinks Per Drinking Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worst facial pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Full-Scale Intelligence Quotient (FSIQ) Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of patients suffering xerostomia ≥ grade 2
Endpoint domain: Adverse events/effects
Primary endpoint: Death (all-cause mortality)
Endpoint domain: Mortality/survival
Primary endpoint: Mortality from hypertension complications
Endpoint domain: Mortality/survival
Primary endpoint: Frequency and Severity of Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: ICRS-Cartilage Repair Assessment Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: impact on serum ALT and AST levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Response (Complete or Partial Remission)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of responsive patients with a given polymorphism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under plasma concentration curve of trastuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration of trastuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion receiving complete PMTCT
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost-effectiveness
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants With Any Significant Comorbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Different Types of Haematological Malignancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With Different Types of Solid Tumour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With Response to Study Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feasibility of the APA
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients followed and treated for hepatitis C
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Standardized Index of Education and Learning (girls)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Standardized index of Bodily Integrity (girls)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Standardized Index of Health, Nutrition, and Sexual and Reproductive Health (girls)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standardized Index of Psychosocial Well-Being (girls)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Standardized Index of Voice and Agency (girls)
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Standardized Index of Economic Empowerment (girls)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Lumbar Spine Bone Mineral Density (LS-BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decline in PSA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All strokes and death within 30 days post-surgery
Endpoint domain: Mortality/survival
Primary endpoint: Ipsilateral recurrent bleeding afterwards
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Deaths Attributable to the Direct Effects of Stroke
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Neurological Deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Glucose TIR (time in range)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose Time below range (hypoglycemia < 70 mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of RT-PCR SARS-CoV-2 positive at 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Quantitative evaluation of nasopharyngeal swab SARS-CoV-2 RT-PCR test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time for flap dissection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in BREAST-Q Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Spatial neglect assessment battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Family caregiver wellness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum tolerated dose of TPI-287
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergency Department Admission Time
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Multifocal electroretinogram responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bladder diary
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adolescent Immunization Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from major adverse cardiac and cerebrovascular events (MACCE)
Endpoint domain: Mortality/survival
Primary endpoint: Normalization of serum LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of elderly patients receiving high-risk medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Severity of vernal keratoconjunctivitis and atopic keratoconjunctivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in thoracic impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of death or major postoperative complications
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence rate of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to recurrence of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinical Cure in the Worse Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes